ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

OCUP Ocuphire Pharma Inc

1.80
0.16 (9.76%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Ocuphire Pharma Inc OCUP NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.16 9.76% 1.80 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.67 1.65 1.99 1.85 1.64
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
08/3/202416:20EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
08/3/202407:21EDGAR2Form 8-K - Current report
16/2/202415:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
16/2/202415:03EDGAR2Form 8-K - Current report
14/2/202417:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202417:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202417:32EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/2/202417:29EDGAR2Form 3 - Initial statement of beneficial ownership of..
23/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
22/1/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/1/202415:16EDGAR2Form S-8 - Securities to be offered to employees in employee..
10/1/202416:00EDGAR2Form S-3 - Registration statement under Securities Act of..
03/1/202417:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202417:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202417:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/12/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202307:45EDGAR2Form 8-K - Current report
13/11/202316:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202316:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202307:48EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202307:12EDGAR2Form 8-K - Current report
03/11/202308:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202308:22EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/11/202307:44EDGAR2Form 8-K - Current report
01/11/202315:21EDGAR2Form 8-K - Current report
27/9/202307:45EDGAR2Form 8-K - Current report
27/9/202307:00PRNUSViatris and Ocuphire Pharma Announce FDA Approval of..
14/8/202307:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/8/202308:27EDGAR2Form 8-K - Current report
11/8/202307:51EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/8/202310:21EDGAR2Form 8-K - Current report

Su Consulta Reciente

Delayed Upgrade Clock